Revenue Update on SciClone Pharmaceuticals(NASDAQ:SCLN)

SciClone Pharmaceuticals(NASDAQ:SCLN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Earnings per share were $0.20.

SciClone Pharmaceuticals (SCLN) shares turned negative on Wednesdays trading session with the shares closing down -0.24 points or -2.27% at a volume of 6,60,313. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $10.61. The peak price level was also seen at $10.61 while the days lowest was $10.0615. Finally the shares closed at $10.33. The 52-week high of the shares is $15.025 while the 52-week low is $6.47. According to the latest information available, the market cap of the company is $516 M.

Several Insider Transactions has been reported to the SEC. On Mar 30, 2016, Friedhelm Blobel (President & CEO) sold 10,000 shares at $9.29 per share price.Also, On Dec 7, 2015, Lan Xie (VP Finance, China CFO) sold 14,166 shares at $9.50 per share price.On Nov 10, 2015, Wilson Wai-shun Cheung (CFO & Senior VP, Finance) sold 7,803 shares at $9.51 per share price, according to the Form-4 filing with the securities and exchange commission.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *